← Back to Directory

Generate Biomedicines, Inc. (GENB) - Latest Market Data

Track the most recent price, market cap, volume, and performance data for Generate Biomedicines, Inc. (GENB).

Get it on Google Play Download on Google Play Download on the App Store Download on the App Store

Equity Details

Price & Market Data

Price: $13.52

Daily Change: -$1.01 / 7.47%

Daily Range: $13.13 - $15.25

Market Cap: $1,710,087,680

Daily Volume: 1,036,988

Performance Metrics

1 Week: -4.72%

1 Month: 12.46%

3 Months: 20.98%

6 Months: 20.98%

1 Year: 20.98%

YTD: 20.98%

About Generate Biomedicines, Inc. (GENB)

Market review of Generate Biomedicines, Inc. (GENB). Current price: 13.52, daily change: -$1.01 / 7.47%. Market cap: 1,710,087,680. All performance figures are updated.

Company Details

Employees: 312

Sector: Health technology

Industry: Biotechnology

Country: United States

Details

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.

Selected stocks

Suja Life, Inc. (SUJA)

Spring Valley Acquisition Corp. IV (SVIV)

Soren Acquisition Corp. (SORN)

Iron Horse Acquisitions II Corp. (IRHO)

Aktis Oncology, Inc. (AKTS)